Tuesday 28th April 2020
Approval of nintedanib for systemic sclerosis-associated interstitial lung disease
Nintedanib, a drug that slows the rate of lung fibrosis, has been approved as a treatment for individuals with systemic sclerosis-associated interstitial lung disease, the first option to have been made available.